Cargando…

Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tampaki, Maria, Ionas, Evangelos, Hadziyannis, Emilia, Deutsch, Melanie, Malagari, Katerina, Koskinas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016746/
https://www.ncbi.nlm.nih.gov/pubmed/31952209
http://dx.doi.org/10.3390/cancers12010212
_version_ 1783497046055976960
author Tampaki, Maria
Ionas, Evangelos
Hadziyannis, Emilia
Deutsch, Melanie
Malagari, Katerina
Koskinas, John
author_facet Tampaki, Maria
Ionas, Evangelos
Hadziyannis, Emilia
Deutsch, Melanie
Malagari, Katerina
Koskinas, John
author_sort Tampaki, Maria
collection PubMed
description Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and the detection of serum programmed death ligand-1 (PD-L1) were assessed. In patients submitted to transarterial chemoembolization (TACE), pre- and 1-week post-treatment TIM-3 levels were also evaluated. We studied 53 HCC patients with BCLC stages: 0 (5.7%), A (34%), B (32.1%), C (22.6%), and D (5.7%). The patients with advanced HCC (BCLC C) had significantly higher TIM-3 levels than patients with BCLC A (p = 0.009) and BCLC B (p = 0.019). TIM-3 levels were not associated with HCC etiology (p = 0.183). PD-L1 detection (9/53 patients) correlated with TIM-3 levels (univariate analysis, p = 0.047). In 33 patients who underwent TACE, post-treatment TIM-3 levels (231 pg/mL, 132–452) were significantly higher than pre-TACE levels (176 pg/mL, 110–379), (p = 0.036). Complete responders had higher post-TACE TIM-3 levels (534 pg/mL, 370–677) than partial responders (222 pg/mL, 131–368), (p = 0.028). Collectively, TIM-3 may have a role in anti-tumor immunity following TACE, setting a basis for combining immunotherapy and chemoembolization.
format Online
Article
Text
id pubmed-7016746
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70167462020-02-28 Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Tampaki, Maria Ionas, Evangelos Hadziyannis, Emilia Deutsch, Melanie Malagari, Katerina Koskinas, John Cancers (Basel) Article Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and the detection of serum programmed death ligand-1 (PD-L1) were assessed. In patients submitted to transarterial chemoembolization (TACE), pre- and 1-week post-treatment TIM-3 levels were also evaluated. We studied 53 HCC patients with BCLC stages: 0 (5.7%), A (34%), B (32.1%), C (22.6%), and D (5.7%). The patients with advanced HCC (BCLC C) had significantly higher TIM-3 levels than patients with BCLC A (p = 0.009) and BCLC B (p = 0.019). TIM-3 levels were not associated with HCC etiology (p = 0.183). PD-L1 detection (9/53 patients) correlated with TIM-3 levels (univariate analysis, p = 0.047). In 33 patients who underwent TACE, post-treatment TIM-3 levels (231 pg/mL, 132–452) were significantly higher than pre-TACE levels (176 pg/mL, 110–379), (p = 0.036). Complete responders had higher post-TACE TIM-3 levels (534 pg/mL, 370–677) than partial responders (222 pg/mL, 131–368), (p = 0.028). Collectively, TIM-3 may have a role in anti-tumor immunity following TACE, setting a basis for combining immunotherapy and chemoembolization. MDPI 2020-01-15 /pmc/articles/PMC7016746/ /pubmed/31952209 http://dx.doi.org/10.3390/cancers12010212 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tampaki, Maria
Ionas, Evangelos
Hadziyannis, Emilia
Deutsch, Melanie
Malagari, Katerina
Koskinas, John
Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
title Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
title_full Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
title_fullStr Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
title_full_unstemmed Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
title_short Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
title_sort association of tim-3 with bclc stage, serum pd-l1 detection, and response to transarterial chemoembolization in patients with hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016746/
https://www.ncbi.nlm.nih.gov/pubmed/31952209
http://dx.doi.org/10.3390/cancers12010212
work_keys_str_mv AT tampakimaria associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma
AT ionasevangelos associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma
AT hadziyannisemilia associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma
AT deutschmelanie associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma
AT malagarikaterina associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma
AT koskinasjohn associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma